Coya Therapeutics Inc (COYA) Implied Volatility Current

Tracking COYA implied volatility helps you identify when options premiums on Coya Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Coya Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when COYA IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Coya Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For COYA, tracking metrics like COYA IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on COYA signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases.

It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where COYA implied volatility sits today versus where it has been. Our scanner ranks Coya Therapeutics Inc implied volatility against its historical range, surfaces extremes in COYA IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Coya Therapeutics Inc IV is rich or cheap — measure it, then act on it.